EICHORCondition: Psoriatic Arthritis · Sponsor: Diakonhjemmet Hospital
Interested? Contact the study team ↓
The main objective is to assess if a treat-to-target strategy implementing structured imaging assessments leads to better patient outcome in terms of sustained remission compared to a conventional treat-to-target strategy in psoriatic arthritis. Main inclusion criteria are: \>18 years of age, Clinical diagnosis of psoriatic arthritis (PsA), Fulfillment of ClASsification of Psoriatic Arthritis (CASPAR) criteria, Indication for treatment with disease modifying anti-rheumatic drugs according to treating physician Primary endpoint: Sustained remission, defined as Very Low Disease Activity (VLDA) at 16, 20 and 24 months Secondary endpoints: Individual and composite disease activity measures and remission criteria, inflammation assessed by ultrasound, health related quality of life and adverse events. Study design: A two-arm, parallel-group, single-blind, treatment strategy study where patients are randomized 1:1 to a conventional treat-to-target follow-up strategy with structured clinical assessment of disease activity or an imaging informed treat-to-target follow-up strategy with both structured clinical assessment of disease activity and structured imaging assessment of disease activity. Duration of follow-up is 24 months. All patients are treated according to an algorithm based on current European recommendations. The conventional treatment target, applicable to both arms and the sole target in the conventional arm, is all of: Disease Activity index in Psoriatic Arthritis …
This description comes directly from the study's public registry record.
Siri Lillegraven, MD, MPH, PhD · +4722451500 · siri.lillegraven@diakonsyk.no
Even Lillejordet, MD · even.lillejordet@diakonsyk.no
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Adult (\>18 years of age) 2. Clinical diagnosis of PsA 3. Indication for treatment with DMARDs according to treating physician (including having attempted ≥2 non-steroidal anti-inflammatory drugs (NSAIDs) for a minimum of 4 weeks in total in predominantly axial and/or entheseal disease) 4. Fulfillment of CASPAR criteria for PsA Exclusion Criteria: 1. Verified arthritis \>1 year prior to inclusion 2. Previous DMARD treatment for PsA 3. Systemic glucocorticoid use within the last 3 months 4. Local glucocorticoid injections within the last 4 weeks 5. Major co-morbidities, including but not limited to relevant malignancies, severe diabetes mellitus, severe infections, uncontrolled hypertension, severe cardiovascular disease (NYHA class III or IV) and/or severe respiratory diseases and cirrhosis. 6. Indications of active or latent tuberculosis (TB) as assessed by chest radiograph and TB interferon gamma release assay (IGRA). Patients with documented adequately treated latent TB can be included. 7. Any other medical condition that according to the treated physician and/or local guidelines makes adherence to treatment protocol impossible 8. Abnormal renal function, defined as serum creatinine \>142 µmol/L in female and \>168 µmol/L in male, or estimated glomerular filtration rate (eGFR) \<40 mL/min/1.73 m2 9. Abnormal liver function (defined as Aspartate Transaminase (AST) and/or Alanine Transaminase (ALT) \>1.5 x upper normal limit), active or recent hepatitis 10. Significant anemia, leukopenia and/or thrombocytopenia 11. Inadequate birth control, pregnancy, and/or breastfeeding (current at screening or planned within the duration of the study) 12. Contraindications to magnetic resonance imaging 13. Severe psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible 14. Established or suspected widespread-pain syndrome/fibromyalgia
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Department of Rheumatology, Helse Møre og Romsdal HF | Ålesund, Norway | Recruiting |
| Department of Rheumatology, Haukeland University Hospital, Helse Bergen HF | Bergen, Norway | Recruiting |
| Department of Rheumatology, Drammen Hospital, Vestre Viken HF | Drammen, Norway | Recruiting |
| Helse Førde | Førde, Norway | Recruiting |
| Haugesunds Sanitetsforening Revmatismesykehus | Haugesund, Norway | Recruiting |
| Sørlandet Sykehus | Kristiansand, Norway | Recruiting |
| Revmatismesykehuset AS | Lillehammer, Norway | Recruiting |
| Helgelandssykehuset, Mo i Rana | Mo i Rana, Norway | Recruiting |
| Department of Rheumatology, Diakonhjemmet Hospital | Oslo, Norway | Recruiting |
| Martina Hansens Hospital AS | Sandvika, Norway | Recruiting |
| University Hospital of Northern Norway | Tromsø, Norway | Recruiting |
| Department of Rheumatology, St Olavs Hospital HF | Trondheim, Norway | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05291819